Adicet Bio, Inc.

ACET Nasdaq CIK: 0001720580

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 131 DARTMOUTH STREET, BOSTON, MA, 02116
Mailing Address 131 DARTMOUTH STREET, BOSTON, MA, 02116
Phone 617-482-2333
Fiscal Year End 1226
EIN 813305277

Financial Overview

FY2024

$33.61M
Total Liabilities
$186.61M
Stockholders' Equity
$159.71M
Cash & Equivalents
$-1.33
EPS

Recent SEC Filings

Form Type Date Filed Document
SCHEDULE 13G Passive beneficial ownership (>5%) January 29, 2026 View on SEC
4 Insider stock transaction report January 27, 2026 View on SEC
4 Insider stock transaction report January 27, 2026 View on SEC
4 Insider stock transaction report January 27, 2026 View on SEC
4 Insider stock transaction report January 27, 2026 View on SEC
8-K Current report of material events January 7, 2026 View on SEC
8-K Current report of material events December 29, 2025 View on SEC
8-K Current report of material events December 19, 2025 View on SEC
DEF 14A Definitive proxy statement November 17, 2025 View on SEC
10-Q Quarterly financial report November 5, 2025 View on SEC

Material Events

8-K Strategy Change December 29, 2025
High Impact
  • Adicet Bio, Inc. announced a 1-for-16 reverse stock split to consolidate shares.
  • The primary goal of the split is to increase the stock price per share to meet Nasdaq listing requirements and potentially attract institutional investors.
View Analysis
8-K Financial Distress December 19, 2025
High Impact
  • Adicet Bio, Inc. shareholders approved a reverse stock split at a Special Meeting on December 19, 2025.
  • The reverse stock split ratio will be determined by the board of directors, ranging from 1-for-5 to 1-for-30.
View Analysis

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.